Phosphorylation of the serine 139 of the histone variant H2AX (γH2AX) is a DNA damage marker that regulates DNA damage response and various diseases. However, whether γH2AX is involved in neuropathic pain is still unclear. We found the expression of γH2AX and H2AX decreased in mice dorsal root ganglion (DRG) after spared nerve injury (SNI). Ataxia telangiectasia mutated (ATM), which promotes γH2AX, was also down-regulated in DRG after peripheral nerve injury. ATM inhibitor KU55933 decreased the level of γH2AX in ND7/23 cells. The intrathecal injection of KU55933 down-regulated DRG γH2AX expression and significantly induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The inhibition of ATM by siRNA could also decrease the pain threshold. The inhibition of dephosphorylation of γH2AX by protein phosphatase 2A (PP2A) siRNA partially suppressed the down-regulation of γH2AX after SNI and relieved pain behavior. Further exploration of the mechanism revealed that inhibiting ATM by KU55933 up-regulated extracellular-signal regulated kinase (ERK) phosphorylation and down-regulated potassium ion channel genes, such as potassium voltage-gated channel subfamily Q member 2 () and potassium voltage-gated channel subfamily D member 2 () in vivo, and KU559333 enhanced sensory neuron excitability in vitro. These preliminary findings imply that the down-regulation of γH2AX may contribute to neuropathic pain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299332PMC
http://dx.doi.org/10.3390/ijms241210148DOI Listing

Publication Analysis

Top Keywords

neuropathic pain
12
γh2ax
10
involved neuropathic
8
dna damage
8
nerve injury
8
down-regulated drg
8
down-regulation γh2ax
8
potassium voltage-gated
8
voltage-gated channel
8
channel subfamily
8

Similar Publications

Purpose: Neuropathic corneal pain (NCP) has been recognized as a distinct disease, yet treatment options remain limited. The aim of this pilot study was to explore the effectiveness of extranasal neurostimulation (EXNS) as a potential pain relief strategy for individuals with the peripheral component of NCP.

Methods: A retrospective study was performed to identify patients who were diagnosed with refractory peripheral or mixed NCP and subsequently underwent a single session of EXNS.

View Article and Find Full Text PDF

A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer.

Pediatr Phys Ther

January 2025

University of North Dakota School of Medicine, Department of Pediatrics, Grand Forks, North Dakota (Ms Washist and Dr Milanovich); Sanford Children's Hospital, Department of Physical Therapy, Sioux Falls, South Dakota (Dr Steventon); Sanford Children's Hospital, Department of Physical Therapy, Fargo, North Dakota (Dr Samuelson); Jamestown University, Department of Physical Therapy, Jamestown, North Dakota (Dr Anderson); University of South Dakota, Department of Physical Therapy, Vermillion, South Dakota (Dr Berg-Poppe); and Sanford Roger Maris Cancer Center, Department of Pediatric Hematology and Oncology, Fargo, North Dakota (Dr Milanovich).

Unlabelled: Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) with associated weakness, areflexia, neuropathic pain, and sensory loss, is a common occurrence in children treated for cancer. However, accurate, quantifiable descriptions of gait deviations due to CIPN are lacking. This scoping review explores common gait abnormalities in children with CIPN.

View Article and Find Full Text PDF

Dorsal Root Ganglion Stimulation for Chronic Pelvic Pain Secondary to Endometriosis.

Neuromodulation

December 2024

Functional and Pain Clinic, Sao Paulo, SP, Brazil; Pediatric Neurosurgery, Washington University in St. Louis, St Louis, MO, USA. Electronic address:

Introduction: Chronic pelvic pain (CPP) is a multifaceted condition that poses significant challenges in clinical management owing to its complex and varied pathophysiology, including neuropathic, somatic, visceral, and musculoskeletal components. Endometriosis is frequently associated with CPP, necessitating a comprehensive, multimodal treatment strategy. This approach typically includes physical and behavioral therapy, pharmacologic interventions, surgical management of endometriosis, and various pain-modulating procedures.

View Article and Find Full Text PDF

Background: Paclitaxel is a widely used anticancer drug for ovarian, lung, breast, and stomach cancers; however, its clinical use is often limited by the side effects of peripheral neuropathy. This study evaluated the effects of () extract and its active metabolite, α-cyperone, on paclitaxel-induced neuropathic pain.

Methods: The oral administration of extract at doses of 500 mg/kg and intraperitoneal administration of α-cyperone at doses of 480 and 800 μg/kg prevented both the development of cold and mechanical pain.

View Article and Find Full Text PDF

Methadone in Cancer-Related Neuropathic Pain: A Narrative Review.

Curr Oncol

December 2024

Division of Palliative Medicine, Department of Internal Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

Cancer-related neuropathic pain (CRNP) is often a significant burden on patients' quality of life. There are limited treatment guidelines for cancer-related neuropathic pain outside of CIPN. Although opioids are considered a third-line treatment option, no consensus exists on which opioid is most effective, either as a single agent or in combination with other medications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!